Thermo Fisher Scientific Stock

$477.41

3.25% yesterday

NYSE, Aug 12, 10:05 pm CET

ISIN

US8835561023

Symbol

TMO

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Overview Dividends Analysts Charts News Strategies

Thermo Fisher Scientific Stock price

$477.41

+61.24 14.72% 5Y

NYSE, Closing price Tue, Aug 12 2025

+15.02 3.25%

ISIN

US8835561023

Symbol

TMO

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Key metrics

Basic

Market capitalization

$174.6b

Enterprise Value

$203.4b

Net debt

$28.8b

Cash

$6.4b

Shares outstanding

377.5m

Valuation (TTM | estimate)

P/E

26.6 | 20.5

P/S

4.0 | 3.9

EV/Sales

4.7 | 4.6

EV/FCF

33.0

P/B

3.5

Dividends

DPS

$1.56

Yield 1Y | 5Y

0.3% | 0.2%

Growth 1Y | 5Y

11.4% | 15.5%

Payout 1Y | 3Y

9.4% | 8.4%

Increased

7 Years

Financials (TTM | estimate)

Revenue

$43.2b | $44.3b

EBITDA

$8.3b | $11.1b

EBIT

$7.9b | $10.0b

Net Income

$6.6b | $8.5b

Free Cash Flow

$6.2b

Growth (TTM | estimate)

Revenue

2.1% | 3.3%

EBITDA

-23.2% | 14.6%

EBIT

5.2% | 29.1%

Net Income

5.8% | 34.4%

Free Cash Flow

-22.5%

Financial Health

Equity Ratio

50.9%

Return on Equity

12.8%

ROCE

8.9%

ROIC

Debt/Equity

0.7

EPS

$17.4

FCF per Share

$16.3

Short interest

1.0%

Employees

125k

Rev per Employee

$340.0k

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

Thermo Fisher Scientific Stock Analysis

Unlock Scores for Free

??

35 Analysts have issued a Thermo Fisher Scientific forecast:

27x Buy

77%

8x Hold

23%

More details on Analyst Estimates Including Price Targets

35 Analysts have issued a Thermo Fisher Scientific forecast:

Buy

77%

Hold

23%

Analyst Estimates with Stock Price Targets

Financial data from Thermo Fisher Scientific

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	43,212 43,212	2% 2% 100%
- Direct Costs	25,350 25,350	1% 1% 59%
Gross Profit	17,862 17,862	3% 3% 41%
- Selling and Administrative Expenses	8,085 8,085	4% 4% 19%
- Research and Development Expense	1,414 1,414	7% 7% 3%
EBITDA	8,286 8,286	23% 23% 19%
- Depreciation and Amortization	429 429	87% 87% 1%
EBIT (Operating Income) EBIT	7,857 7,857	5% 5% 18%
Net Profit	6,584 6,584	6% 6% 15%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Thermo Fisher Scientific Stock News

Positive

Seeking Alpha

●

one day ago

Thermo Fisher: Growth Acceleration And Margin Expansion Should Drive The Upside

Revenue growth is accelerating, led by pharma/biotech momentum and bioproduction demand. The medium-term margin outlook is positive with cost cuts, AI-driven efficiencies, and lapping of tariff headwinds starting next year. Valuation attractive vs. history and peers, supporting potential re-rating.

Neutral

Business Wire

●

one day ago

Thermo Fisher Receives FDA Approval for NGS-Based Companion Diagnostic for New Non-Small Cell Lung Cancer Treatment

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS® (zongertinib tablets), a tyrosine kinase inhibitor (TKI), developed by Boehringer Ingelheim. The test allo...

Positive

Seeking Alpha

●

4 days ago

Thermo Fisher: The Rerating Is Just Getting Started - Buy

Thermo Fisher is emerging from a challenging period with solid fundamentals, strong cash flow, and renewed growth, making it undervalued by the market. Recent earnings showed organic growth, margin expansion, and raised guidance, signaling a return to normalcy and operational strength. Valuation models indicate 15–48% upside, driven by recurring revenues, loyal customers, and potential for mult...

More Thermo Fisher Scientific News

Company Profile

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Head office	United States
CEO	Marc Casper
Employees	125,000
Founded	1960
Website	www.thermofisher.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now